Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

HaemoAdsorption Nach Reanimation An ECMO (HANRAE)

10 de agosto de 2018 atualizado por: Universitätsklinikum Hamburg-Eppendorf

This study evaluates the use of an additional hemoadsorption device in adult patients undergoing veno-arterial extracorporal membrane oxygenation (ECMO) following cardiac arrest and cardiopulmonary resuscitation in respect to its effects on post resuscitation inflammatory syndrome.

At implantation of the ECMO the participants are going to be randomized into a treatment and a control group. The first will be outfitted with a polymer-based adsorption device implemented in the extracorporal circulation established by ECMO for 48h, the control group is going to be treated by ECMO and standard intensive care alone. To detect any significant differences in terms of inflammatory response and patient outcome the investigators will regularly determine the blood levels of certain cytokines in fixed intervalls. In addition, the investigators are going to compare secondary clinical outcome parameters like organ disfunction and 30d mortality.

Visão geral do estudo

Descrição detalhada

Even after successful return of spontaneus circulation (ROSC), patients suffering a cardiac arrest with subsequent cardipulmonary resuscitation (CPR) are still facing a significant morbidity and mortality in the post-resuscitation phase. They are nowadays often subjected to extracorporal membrane oxygenation (ECMO), supplementing or even replacing cardiac and/or pulmonary function for a certain period in order to reduce the workload for these critical organs. However, as well as the initial ischemia/reperfusion damage, subsequent procedures create significant stress to the patients organism, causing severe inflammation and contributing to post-resuscitation single or multiple organ disfunction and/or failure.

Continously eliminating relevant mediators of inflammation by adsorption to a polymer-based material in extracorporal circulation has been shown to influence the course of this inflammatory syndrome in patients with severe infection and sepsis. Any relevant clinical studies evaluating the use of such a device in post-resuscitation care are still lacking, yet.

Therefore, in this study the investigators are going to test the hypothesis that such a device is capable of significantly altering the cytokine levels during and even shortly after a 48h treatment period in addition to the standard ECMO therapy all patients are going to receive. As a secondary outlook, the investigators are going to compare the clinical outcome of the patients in terms of major organ disfunction and overall 30d mortality.

At the time extracoporal circulation is established during or after CPR, all participants (n=40) are enrolled and randomized into a treatment and a control group. The extracorporal circulation over the ECMO device is then outfitted with a certified in line adsorption cartridge for the treatment group. Due to technical reasons, this cartridge has to be exchanged for another identical module after 24h of continuous treatment. Adsorption therapy is terminated after 48h. The control group is subjected to ECMO without any additional modules. Both groups are receiving standard intensive care during the course of the study. All diagnostic and therapeutic decisions with the exemption of those directly concerning the hemoadsorption and sampling protocol are at sole discretion of the clinical staff.

For both groups, blood samples are taken at time points 0,6,12,24,36,48,72h after establishment of ECMO or time of death, respectively. Relevant parameters are then determined in different diagnostic and research laboratories with/without sample preprocessing by the study personal in accordance with preanalytic requirements. All relevant clinical data is extracted from the digital patient data management system (PDMS).

Tipo de estudo

Intervencional

Inscrição (Antecipado)

40

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Hamburg, Alemanha, 20246
        • Recrutamento
        • University Hospital Hamburg-Eppendorf
        • Contato:
          • Jens Kubitz, Prof. Dr.
          • Número de telefone: +49 (0) 40 7410 - 52415
          • E-mail: j.kubitz@uke.de
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

All patients receiving a veno-arterial ECMO after cardiac arrest at the study site are eligible for the study. Thus, the criteria are defined by the SOP "ECMO bei Reanimation" of the University Heart Center Hamburg:

Inclusion Criteria:

  • observed cardiac arrest with initial hyperdynamic rhythm and sufficient primary resuscitation

Exclusion Criteria (absolute):

  • existing "do-not-resuscitate"-order from the patient/a priori palliative situation
  • severe trauma
  • severe acute bleeding due to any cause
  • confirmed or highly likely relevant and severe persistent neurologic impairment
  • severe limiting comorbidities with independent and relevant reduction of life expectancy (e.g. malignoma, preexistent heart failure syndrome, obstructive/restrictive lung disease, hepatic cirrhosis)

Exclusion Criteria (relative, at the discretion of the responsible provider):

  • severe initial lacacidosis
  • prolongued mechanical resuscitation (>30min)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment
Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
see arm description
Sem intervenção: Control
ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
IL-6 at hour 6
Prazo: 6 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
6 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 12
Prazo: 12 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
12 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 24
Prazo: 24 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
24 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 48
Prazo: 48 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
48 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 72
Prazo: 72 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of interleukine 6 will be compared between intervention and control group
72 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 6
Prazo: 6 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
6 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 12
Prazo: 12 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
12 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 24
Prazo: 24 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
24 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 48
Prazo: 48 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
48 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 72
Prazo: 72 hours post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group
72 hours post establishment of extracorporal membrane oxygenation (ECMO)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
S1P
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Blood levels of sphingosine-1-phosphate will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PCT
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of procalcitonine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CRP
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of C-related peptide will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Leukocytes
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The number of leukocytes in simple blood count will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BNP
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of n-terminal pro brain natriuretic peptide will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mean arterial pressure (MAP)
Prazo: Continuosly from enrollment to 72h post.
The mean arterial pressure as calculated automatically from the invasively measured arterial pressure curve will be compared between intervention and control group.
Continuosly from enrollment to 72h post.
Heart rate (HR)
Prazo: Continuosly from enrollment to 72h post.
The continuously monitored heart rate will be compared between intervention and control group.
Continuosly from enrollment to 72h post.
Central venous pressure (CVP)
Prazo: Continuosly from enrollment to 72h post.
The continuously and invasively measured mean central venous pressure will be compared between intervention and control group, if available.
Continuosly from enrollment to 72h post.
haemodynamically relevant medication
Prazo: Continuosly from enrollment to 72h post.
The continuous intake of the following drugs as chosen by discretion of the clinical staff is extracted from digital PDMS: Norepinephrine, Epinephrine, Dobutamin, inodilatators (Milrinon, Enoximon, Levosimendan)
Continuosly from enrollment to 72h post.
Trop
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of troponine T will be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CK
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Plasma levels of creatinkinase will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Myoglobine
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Serum levels of myoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Hemoglobine
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The total blood concentration of hemoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Haptoglobine
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of haptoglobine will be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paO2
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The arterial partial pressure of oxygen as measured by point-of-care blood gas analysis is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paCO2
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The arterial partial pressure of carbon dioxide as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SaO2
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The saturation of hemoglobine with oxygen in an arterial blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SvO2
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The saturation of hemoglobine with oxygen in a central venous blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Horowitz index
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The Horowitz index, calculated as paO2/FiO2 is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
pH
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The pH of an arterial blood sample is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
HCO3
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The levels of bicarbonate of an arterial blood sample are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BE
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The base excess of an arterial blood sample is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
N
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of sodium are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
K
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of potassium are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
C
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of chloride are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Lactate
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The blood levels of lactate are going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mode of Ventilation
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The mode of mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
FiO2
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The inspiratory oxygen fraction at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Peak inspiratory pressure (pmax)
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The peak inspiratory pressure at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PEEP
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The positive end exspiratory pressure at mechanical ventilation is going to be compared between intervention and control group
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Ventilation frequency
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The frequency of mechanical ventilation (cycles/min) is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Tidal volume
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The tidal volume achieved by mechanical ventilation is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Total minute ventilation
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The total minute ventilation as measured by the ventilation unit is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Complicance
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The airway compliance (c) as calculated from ventilator driving pressure(dp=pmax-PEEP) and tidal volume (V): c=V/dp is going to be compared between intervention and control group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ASAT
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of asparic acid aminotransferase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ALAT
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma levels of alanin aminotransferase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
INR
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The thrombin time as standardized international normal ratio will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
apTT
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The activated partial thromboplastin time will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Crea
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The plasma creatinine concentration will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
eGFR
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The glomerulary filtration rate, estimated from serum creatinine by the CKP-EPI formula will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Volume status
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
For a clinical estimation of the renal function, the following parameters are extracted from the digital PDMS: Fluid intake, diuresis, additional loss of body fluids (e.g. gastral reflux, vomitting, extraction by kidney replacement therapy)
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
NSE
Prazo: at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
The serum levels of neuron specific enolase will be compared between intervention and treatment group.
at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mortality
Prazo: 30 days post enrollment
Mortality within 30 days after enrollment due to any cause will be determined, if follow up is technically feasible
30 days post enrollment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jens Kubitz, Prof. Dr., Universitätsklinikum Hamburg-Eppendorf

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Antecipado)

1 de outubro de 2018

Conclusão Primária (Antecipado)

1 de maio de 2019

Conclusão do estudo (Antecipado)

1 de setembro de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

3 de maio de 2018

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de agosto de 2018

Primeira postagem (Real)

16 de agosto de 2018

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de agosto de 2018

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de agosto de 2018

Última verificação

1 de agosto de 2018

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • UKEHANRAE

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever